Use of SGLT-2 Inhibitor in Decompensated Heart Failure Presenting with Bilateral Resistant Pleural Effusion

Authors : Esra KAYA, Ümmügülsüm AKPINAR, Banu TAŞKIRAN TATAR, Nizameddin KOCA

Pages : 172-174

Doi:10.46310/tjim.1078269

View : 23 | Download : 6

Publication Date : 2022-04-01

Article Type : Other Papers

Abstract :Chronic diseases concomitantly decrease quality of life and lifespan expectancy. Novel medications, including Sodium-glucose-co-transporter-2 inhibitors insert ignore into journalissuearticles values(SGLT-2i);, affect both diabetes, heart failure, and diabetic kidney disease. These multisystemic effects give patients with mono systemic and multisystemic diseases new treatment options. Recent studies have shown that SGLT2i may benefit heart failure patients without diabetes. In this case report, we presented a 65-years old patient who was admitted to the emergency room with shortness of breath. Bilateral pleural effusion was observed in the chest X-ray. After etiological studies, empagliflozin was initiated for pleural effusion, which is thought to be related to heart failure. The patient’s symptoms declined on the fourth day of the treatment, and the control lung X-ray revealed that the effusions declined.
Keywords : pleural effusion, heart failure, SGLT 2 inhibitors